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Abstract: Parkinson’s disease (PD) is one of the most common neurodegenerative disorders and is
characterized by the loss of dopaminergic neurons in the substantia nigra (SN). Although the causes
of PD are not understood, evidence suggests that its pathogenesis is associated with oxidative
stress and inflammation. Recent studies have suggested a protective role of the cannabinoid
signalling system in PD. β-caryophyllene (BCP) is a natural bicyclic sesquiterpene that is an agonist
of the cannabinoid type 2 receptor (CB2R). Previous studies have suggested that BCP exerts
prophylactic and/or curative effects against inflammatory bowel disease through its antioxidative
and/or anti-inflammatory action. The present study describes the neuroprotective effects of BCP in
a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced murine model of PD, and we report
the results of our investigation of its neuroprotective mechanism in neurons and glial cells. In the
murine model, BCP pretreatment ameliorated motor dysfunction, protected against dopaminergic
neuronal losses in the SN and striatum, and alleviated MPTP-induced glia activation. Additionally,
BCP inhibited the levels of inflammatory cytokines in the nigrostriatal system. The observed
neuroprotection and inhibited glia activation were reversed upon treatment with the CB2R selective
antagonist AM630, confirming the involvement of the CB2R. These results indicate that BCP acts via
multiple neuroprotective mechanisms in our murine model and suggest that BCP may be viewed as
a potential treatment and/or preventative agent for PD.
Keywords: β-caryophyllene; Parkinson’s disease; MPTP; microglial activation
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1. Introduction
Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by the
progressive degeneration of nigrostriatal dopaminergic (DA) neurons. The most prominent biochemical
changes in PD involve the reduction of striatal dopamine levels, which may result in abnormal motor
behaviour, including resting tremors, rigidity, and bradykinesia [1]. The incidence of PD increases
with age [2], and PD affects approximately 6% of those over the age of 65. Even in the beginning
stages, PD can lead to significant dysphagia that negatively impacts the quality of life [3]. The primary
neurodegeneration trigger remains uncertain; however, several pathophysiological mechanisms have
been implicated, including ageing, highly dense microglia in the substantia nigra (SN), inflammation,
oxidative/nitrosative stress, abnormal protein deposits, and decreased neurotrophic factors [4]. These
mechanisms lead to microglia activation, which, in turn, favours an oxidative and inflammatory
environment that is facilitative of neuronal death [5]. In the substantia nigra of PD patients and in
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) models of PD, key enzymes involved in reactive
oxygen species (ROS) production, such as microglia NAPDH oxidase, are upregulated in damaged
areas and contribute to DA neuronal cell death [6]. In addition, proinflammatory cytokines, such as
IL-1βand TNF-α, are augmented in PD patients [7,8] and participate in DA neuronal cell death in the
MPTP model of PD [9,10].
Recent studies have suggested that the cannabinoid signalling system plays a protective role in
PD. For example, during PD, endocannabinoids accumulate, cannabinoid receptors are upregulated,
and treatment with cannabinoid agonists, either endocannabinoids or phytocannabinoids/synthetic
cannabinoids, protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting
microglia activation [11].
The effects of cannabinoids are mainly mediated by the action of G-protein-coupled type 1
cannabinoid receptors (CB1Rs) and type 2 cannabinoid receptors (CB2Rs). CB2Rs were initially
thought to be expressed primarily in activated microglia and peripheral immune cells where they
regulate cytokine/chemokine production and cell migration [12]. Numerous in vitro studies have
shown that microglia activation of the CB2R inhibits the release of proinflammatory cytokines [13] and
increases the release of anti-inflammatory cytokines. On the other hand, in vivo studies have shown
that pharmacological activation of the CB2R can reduce the activation of microglia cells and inhibit
dopaminergic cell death in the substantia nigra in PD models [14]. Moreover, genetic studies have
supported these pharmacological findings, with CB2R knock-out mice displaying increased microglia
activation, neural pathology and functional deficits in models of PD [15]. Post-mortem studies of
human patients with PD have revealed that the CB2R levels were elevated in microglial cells in the
substantia nigra of PD patients [16]. Although a great amount of evidence has indicated the presence
of functional CB2Rs in the central nervous system (CNS), potential neuroprotective properties of these
CB2Rs and the molecular mechanisms underlying the effects associated with their activation during PD
are not yet understood. In addition, an important advantage of compounds that specifically activate
CB2R is that they do not cause any of the effects frequently associated with psychotropic cannabinoids
that activate the CB1R, indicating that can be safe and well-tolerated in clinical applications.
β-Caryophyllene (BCP) is a natural bicyclic sesquiterpene isolated from clove leaf oil, clove stem
oil, cinnamon leaf oil, and pine oil fractions. It has been used as a flavouring agent and as a fragrance
ingredient since the 1930s [17]. Further, it has been granted the generally recognized-as-safe (GRAS)
status by the Flavour and Extract Manufacturers Association and is approved by the U.S. FDA for use in
food because of its low toxicity. This compound is known to be antimicrobial [18], antioxidant [19] and
anticarcinogenic [20], and it also possesses properties that enhance skin penetration [21]. Specifically,
essential oils that have BCP as a major component (30.6%) have shown obvious anti-inflammatory
activity against carrageenan- and prostaglandin E (PGE) 1-induced oedema in rats as well as
antiarthritic activity [22,23]. Recently, it has been demonstrated that BCP exerts prophylactic and/or
curative effects against inflammatory bowel disease through its antioxidative and/or anti-inflammatory
action [24]. Like other CB2R agonists, trans-caryophyllene inhibits inflammation, oedema formation,
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and the expression of inflammatory mediators in vitro and in vivo. Thus, we hypothesized that BCP
may improve motor behaviour and prevent the loss of nigrostriatal dopaminergic neurons by inhibiting
brain inflammation and oxidative stress in an experimental model of Parkinson’s disease. However,
the influence of BCP on PD has not yet been explored.
2. Results
2.1. Motor Behavioural Test: β-Caryophyllene Inhibits Chronic MPTP-Induced Defects in Motor Coordination
via the CB2 Receptor
2.1.1. Pole Test Analysis
The effects of BCP administered both intraperitoneally and orally on mouse motor function were
assessed with the pole test. Mice were examined under baseline conditions prior to the administration
of MPTP. Deficits in motor coordination were clearly observed in the MPTP-treated mice, with the
most severe motor function impairment being 16.5 ± 1.7 s required for the mice to turn at the top of
the pole and climb down in comparison to that of the control group. Administration of 10 mg/kg BCP
both orally and intraperitoneally prior to the administration of MPTP significantly showed a recovery
effect on the MPTP-induced movement impairment (intraperitoneal: 7.3 ± 1.5 s; oral: 5.7 ± 1.8 s).
AM630 (3 mg/kg, i.p.) significantly reversed the BCP-induced improvement in the pole test (p < 0.01).
In the groups treated only with BCP and AM630, no statistically significant changes compared to the
control group were observed (Figure 1).
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2.1.2. Gait Test Analysis 
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the group treated with MPTP, decreased stride length relative to that of the control group was 
observed. However, in the groups treated with BCP (10 mg/kg, i.p.) administered both orally and 
intraperitoneally prior to MPTP administration, an increase in stride length compared to that of the 
MPTP-treated group was observed. AM630 (3 mg/kg, i.p.) significantly reversed the BCP-induced 
improvement in the gait test (p < 0.01). In the groups treated with only BCP or AM630, no statistically 
significant changes were observed compared to the control group (Figure 2). 
Figure 1. The pole test. The protective effects of BCP administ red both intraperitoneally (A) and
orally (B) against MPTP-induced b havioural impairment in mice. MPTP-treated mice displayed
a significant increase in the total time required to traverse the pole 3 d post lesion relative to that
of the CTL-injected mice. The data are presented as mean ± SEM of six individual experiments.
Intraperitoneal: *** p < 0.001, CTL vs. MPTP. ** p < 0.01, MPTP vs. BCP + MPTP. ** p < 0.01, CTL vs.
AM630 + BCP + MPTP treatment. Oral: *** p < 0.001, CTL vs. MPTP. ** p < 0.01, MPTP vs. BCP + MPTP.
*** p < 0.001, BCP vs. MPTP treatment.
2.1.2. Gait Test Analysis
On th other hand, a sho tened shift stride is considered a symptom of Parkinson’s disease.
In the group tre ted with MPTP, decrea ed stride length rela ive to that f the control group was
observed. However, in the groups treated with BCP (10 mg/kg, i.p.) administered both orally and
intraperitoneally prior to MPTP administration, an increase in stride length compared to that of the
MPTP-treated group was observed. AM630 (3 mg/kg, i.p.) significantly reversed the BCP-induced
improvement in the gait test (p < 0.01). In the groups treated with only BCP or AM630, no statistically
significant changes were observed compared to the control group (Figure 2).
Pharmaceuticals 2017, 10, 60 4 of 18
Pharmaceuticals 2017, 10, 60 4 of 18 
 
 
Figure 2. The gait test. The protective effects of BCP administered both intraperitoneally (A) and 
orally (B) against MPTP-induced behavioural impairment in mice. The MPTP-lesioned mice exhibited 
a significant decrease in the average stride length 3 days post-lesion compared to that of the CTL-
treated mice. The data are presented as the mean ± SEM of six individual experiments. Intraperitoneal: 
** p < 0.01, CTL vs. MPTP. * p < 0.05, MPTP vs. BCP+MPTP. * p < 0.05, MPTP vs. AM630 + BCP + MPTP 
treatment. Oral: * p < 0.05, CTL vs. MPTP. ** p < 0.01, BCP vs. MPTP. * p < 0.05, MPTP vs. BCP + MPTP 
treatment. 
2.1.3. Beam Test 
Motor defects of animals from each of the treatment groups to navigate the balance beam was 
evaluated to study this aspect. Figure 3 shows that the average time it took the control mice to cross 
the beam was 8 s, while mice exposed to MPTP took 11.8 s to cross the beam, which was statistically 
significant compared to that of the group control.  
 
Figure 3. The beam test. The protective effects of BCP administered both intraperitoneally (A) and 
orally (B) against MPTP-induced behavioural impairment in mice. MPTP-lesioned mice exhibited a 
significant decrease in the average time required to cross the beam 3 days post-lesion compared to 
that of the CTL-treated mice. The data are presented as the mean ± SEM of six individual experiments. 
Intraperitoneal: ** p < 0.01, CTL vs. MPTP. ** p < 0.01, MPTP vs. BCP + MPTP. * p < 0.05, CTL vs. 
AM630 + BCP + MPTP treatment. Oral: * p < 0.05, CTL vs. MPTP. * p < 0.05, BCP vs. MPTP. * p < 0.05, 
MPTP vs. BCP + MPTP treatment. 
Figure 2. The gait test. The protective effects of BCP administered both intraperitoneally (A)
and orally (B) against MPTP-induced behavioural impairment in mice. The MPTP-lesioned mice
exhibited a significant decrease i the av rage stride length 3 days post-lesion compared to that of
the CTL-treated mice. The data are presented as the mean ± SE of six individual experiments.
Intraperitoneal: ** p < 0.01, CT s. MPTP. * p < 0.05, MPTP vs. BCP + MPTP. * p < 0.05, MPTP vs.
AM630 + BCP + MPTP treatment. Oral: * p < 0.05, CTL vs. MPTP. ** p < 0.01, BCP vs. MPTP. * p < 0.05,
MPTP vs. BCP + MPTP treatment.
2.1.3. Beam Test
Motor defects of animals from each of the treatment groups to navigate the balance beam was
evaluated to s udy this aspect. Figure 3 shows that the average time it took the control mice to cross
the beam was 8 s, while mice exposed to MPTP took 11.8 s to cross the beam, which was statistically
significant compared to that of the group control.
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a significant decrease in the average time required to cross the beam 3 days post-lesion co pared to
that of the CTL-treated mice. The data are presented as the mean ± SEM of six individual experiments.
Intraperitoneal: ** p < 0.01, CTL vs. MPTP. ** p < 0.01, MPTP vs. BCP + MPTP. * p < 0.05, CTL vs.
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In contrast, in the groups treated with BCP (10 mg/kg, i.p.) administered both orally and
intraperitoneally prior to the administration of MPTP, a decrease in the time it took the animals to cross
the beam of 7.5 s intraperitoneally and 7.5 s orally was observed, which was statistically significant
with respect to that of the MPTP treatment group. AM630 (3 mg/kg, i.p.) significantly reversed the
BCP-induced improvement in the beam test (p < 0.01). In the groups treated with only BCP or AM630,
no statistically significant changes were observed compared to the control group.
2.2. β-Caryophyllene Prevents Chronic MPTP-Induced Dopaminergic Neuron Loss in the SNpc and STR via
the CB2 Receptor
TH-immunoreactivity was measured in the SNpc and STR to explore the effects of BCP on the
MPTP-induced degeneration of dopaminergic neurons. Treatment with MPTP significantly reduced
the number of TH-IR neurons by 74% compared with that of the control mice. However, in mice
treated with BCP (10 mg/kg, i.p.) and MPTP, the number of dopaminergic neurons was reduced
by only 18.4 ± 3.4% compared with that of the control. To determine whether the protective effect
of BCP against MPTP-induced dopaminergic neuronal degeneration was mediated by CB2R, mice
were pretreated with the CB2R selective antagonist AM630 (3 mg/kg, i.p.) 30 min prior to BCP
administration. AM630 significantly reversed the protective effect of BCP, as evidenced by a reduction
in the number of dopaminergic neurons (79 ± 1.7%) compared with that of the control mice (p < 0.01;
Figure 4). Systemic administration of BCP or AM630 by themselves did not significantly affect the
number of TH-immunoreactive cells (p < 0.05 compared with that of the controls).
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Figure 4. BCP treatment attenuates the MPTP-induced nigrostriatal dopaminergic neuronal damage.
C57BL/6 mice were treated with MPTP for 5 days (30 mg/kg, i.p.). The mice were sacrificed on
the 3rd day after MPTP injection after being subjected to behavioural tests. Photomicrographs of
representative SN (A) sections stained with an antibody against TH. Reduced activity of TH-neurons
was observed in the MPTP-treated mice, which was partially prevented by treatment with BCP. The
number of TH-positive neurons in the SN (B) was expressed as the mean ± SEM of six individual
experiments. *** p < 0.001, CTL vs. MPTP treatment. * p < 0.05, MPTP treatment vs. BCP + MPTP
treatment. *** p < 0.001, CTL vs. AM630 + BCP + MPTP treatment.
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Densitometric analysis showed that the number of TH-positive fibres in the STR was decreased
by 61% after MPTP administration compared to that of the control group (p < 0.001). By contrast, mice
treated with BCP (10 mg/kg, i.p.) and MPTP displayed an increased number of TH-positive fibres
in the STR compared to that of the MPTP group (p < 0.001). In mice treated with BCP and MPTP,
the number of TH-positive fibres was reduced by only 17.4 ± 5.4% compared with that of the control
mice. AM630 significantly reversed the protective effect of BCP, as evidenced by a reduction in the
number of TH-positive fibres in the STR (47.7 ± 1.7%) compared with that of the control mice (p < 0.05;
Figure 5). Systemic administration of BCP did not significantly affect the number of TH-positive fibres.
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and the microglia marker IBA-1 were detected by immunohistochemistry. Chronic administration of 
MPTP (30 mg/kg, i.p.) markedly activated astrocytes (Figure 6) and microglia (Figure 7) in the mouse 
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Figure 5. BCP treatment attenuates MPTP-induced nigrostriatal dopaminergic neuronal damage.
C57BL/6 mice were treated with MPTP for 5 days (30 mg/kg, i.p.). The mice were sacrificed on
the 3rd day after MPTP injection after being subjected to behavioural tests. Photomicrographs of
representative STR (A) sections stained with an antibody against TH. Reduced activity of TH-neurons
was observed in the MPTP-treated mice, which was partially prevented by treatment with BCP. The
number of TH-positive fibres in the STR (B) was expressed as the mean ± SEM of six individual
experiments. *** p < 0.001, CTL vs. MPTP treatment. * p < 0.05, MPTP treatment vs. BCP + MPTP
treatment. *** p < 0.001, CTL vs. AM630 + BCP + MPTP treatment.
2.3. β-Caryophyllene Inhibits Chronic MPTP-Induced Astrocyte and Microglia Activation in the SNpc and
STR via the CB2 Receptor
To evaluate the effects of BCP on astrocyte and microglia activation, the astrocyte marker GFAP
and the microglia marker IBA-1 were detected by immunohistochemistry. Chronic administration of
MPTP (30 mg/kg, i.p.) markedly activated astrocytes (Figure 6) and microglia (Figure 7) in the mouse
SNpc, as evidenced by significantly increased numbers of GFAP-IR cells (163.2% compared with that
of the control mice) and IBA-1-IR cells (46.2% compared with that of the control mice).
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Figure 6. Effect of BCP on MPTP-induced astrocyte activation in the mouse SNpc. (A) Glial fibrillary
acidic protein (GFAP)-IR astrocytes in mouse SNpc. Scale bar: 200 µm. (B) Stereological cell counts of
GFAP-IR neurons. The data are presented as the mean± SEM of six individual experiments. ** p < 0.01,
CTL vs. MPTP treatment. ** p < 0.01, MPTP treatment vs. BCP + MPTP treatment. *** p < 0.001, CTL
vs. AM630 + BCP + MPTP treatment.
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Treatment with 10 mg/kg BCP (10 mg/kg, i.p.) suppressed the MPTP-induced increase in
GFAP-IR cells and IBA-1-IR cells by 84.5 and 66.2%, respectively, (p < 0.01) compared with the effects
of MPTP treatment alone. The protective effect of BCP against astrocyte activation and microglia
was fully reversed by pre-treating with 3 mg/kg AM630. Systemic administration of BCP alone not
significantly affect the numbers of GFAP-IR or IBA-1-IR cells (p < 0.05 compared with that of the
control mice) (Figures 6 and 7).
Regarding the effect of BCP on astrocyte and microglia activation in the striatum, markedly
activated astrocytes (Figure 8) and microglia (Figure 9) were observed in the mice that were
administered MPTP (30 mg/kg, i.p.), as evidenced by a significant increase in GFAP-IR cell numbers
(257% compared with that of the control mice) and IBA-1-IR cell numbers (97.4% compared with
that of the control mice). Treatment with 10 mg/kg BCP suppressed the MPTP-induced increase in
GFAP-IR cell numbers and IBA-1-IR cell numbers by 323.5% and 32%, respectively, (p < 0.01) compared
with the effects of MPTP treatment alone. The protective effect of BCP against astrocyte and microglia
activation was fully reversed by pretreatment with 3 mg/kg AM630. Systemic administration of BCP
alone did not significantly affect the number of GFAP-IR or IBA-1-IR cells (Figures 8 and 9).
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3. Discussion
Various experimental evidence has shown that the endocannabinoid system is a target of
pharmacological regulation for the treatment of PD [25]. In the pathology of PD, neuronal death
and injury in the SNpc is caused by an inflammatory process largely mediated by the activation of glial
cells. A very constant pathogenic condition in PD is oxidative damage leading to the degeneration
of dopaminergic cells through the generation of reactive oxygen species (ROS), which ultimately
potentiates the MPTP-induced neurotoxicity. It is well known that inflammatory mediators, such
as nitric oxide (NO), chemokines and cytokines, play an important role in neuronal cell damage
associated with glial cells, which is a crucial neuroinflammatory process involved in the initiation and
development of neurodegenerative disorders such as PD [26]. Recently, it has been shown that the
use of phytocannabinoid drugs can regulate the activation of glial cells and exert a neuroprotective
effect against neuronal damage induced by MPTP, which constitutes an attractive framework for the
development of neuroprotective agents against PD. A study published by Gertsch et al., showed
that BCP selectively binds the CB2R [27]. Specifically, CB2R ligands, which have been shown
to inhibit carrageen-induced mouse paw oedema [28], act on primary afferent neurons to inhibit
nociception [29] and play a protective role in hepatic ischaemia reperfusion injury [30]. The use of
BCP could offer this neuroprotective function without the psychotropic effects that occur when the
CB1R is activated. This suggests that this selective CB2R agonist could potentially be a neuroprotective
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agent for neurodegenerative diseases, such as PD. Moreover, the endocannabinoid system modulates
inflammatory responses through microglia and astroglia function, either by a receptor-dependent or
an independent mechanism [31,32]. There are several reports that describe increased CB2R expression
in the brain under pathological conditions, mainly in glial cells, which represents a potential therapeutic
target for the inhibition of MPTP-induced neuronal damage [16,33,34]. In agreement with previous
studies, MPTP administration in rodents produces a robust glia reaction, characterized by activated
microglia and reactive astrocytes in the ventral midbrain. A similar reaction has been reported
in the brain of PD patients [35]. As expected, in our experimental model, we observed enhanced
immunoreactivity of GFAP-labelled astrocytes and IBA-1-labelled microglia in the SN and striatum of
MPTP-treated mice, suggesting that reactive glial cells may play a key role in brain regions damaged
by MPTP. In addition, we found that systemic administration of BCP significantly alleviated the
MPTP-induced perturbed behavioural symptoms, improved the compromised motor coordination,
protected against the degeneration of dopaminergic neurons, and suppressed the production of
proinflammatory cytokines, including IL-6 and IL-1β, in the SN. In this sense, several lines of evidence
suggest microglia-derived proinflammatory cytokines may be involved in nigrostriatal DA neuronal
cell death. Studies of post-mortem PD subjects and models of induced PD show the presence of
activated glial cells expressing proinflammatory cytokines, such as IL-1β and TNF-α, in the SN.
IL1-β and TNF-α released from glial cells lead to intracellular death-related signalling pathways
in the MPTP model of PD. This is comparable tofinding described that activated microglia-derived
IL-1β, IL-6 and TNF-α participated in DA neuronal cell death in an MPTP murine model of PD [36].
Additionally, our ELISA data showed that the activation of CB2R through the administration of BCP
attenuated the MPTP-induced increases in IL-1β and IL-6 in the SN. Price and colleagues showed
that WIN55,212-2 prevents dopaminergic cell death induced by MPTP through the inhibition of
microglial cells [15]. These results were reversed by treatment with the CB2R antagonist JTE in
MPTP-treated mice, indicating the possible involvement of the microglia CB2R. This is in accordance
with our observations that the CB2R antagonist AM630 inhibited the neuroprotective effect of the
selective CB2R agonist BCP in MPTP-treated mice. These results demonstrate that it is possible
that the activation of the CB2R, at least in part, participates in DA neuronal cell survival through
the inhibition of glia activation in an MPTP murine model, although further studies are required to
determine the underlying mechanisms. Moreover, the work done by Chung in 2010 demonstrated
that the cytokine IL-1β directly participates in MPTP-induced cell death. In this work, the authors
also demonstrated that the activation of the CB1R reduces the expression levels of IL-1β in the SN
of MPTP-treated mice and that this neuroprotective action was reversed after the administration
of specific antagonists to the CB1R and CB2R [6]. These results demonstrate that the activation of
cannabinoid receptors can induce a phenotype change of M1 (IFN-γ, TNF-α and IL-2) to M2 (IL-4 and
IL-5) through a CB2 receptor-dependent mechanism mediated by anti-inflammatory actions, which
can contribute to the neuroprotective effect [34]. An important cytokine in the establishment of the
M2 phenotype is IL-10 [37,38]. Anandamide treatment induced an increase in the production of IL-10,
mediated by the CB2R, as determined by the fact that blocking this receptor with a specific antagonist
(SR2SR145228) reversed this effect. Additionally, use of the CB2R specific agonist JWH-133 produced
similar effects as the AEA treatment.
During an inflammatory process astrocytes and microglia cells, in addition to secreting
mediators of inflammation, such as IL-6, IL-1β, TNF-α, nitric oxide and reactive oxygen species
that exert neurotoxic effects during pathological states [39], which can contribute significantly
to the neurodegenerative process underlying PD [40,41]. In addition, these cells are able to
release endocannabinoids to combat various neuropathological conditions [42] and traumatic CNS
lesions [43].These neuroinflammatory processes require a delicate balance between the production of
pro- and anti-inflammatory cytokines [44] so that inflammation is maintained within appropriate limits.
Many studies have reported that the activity of neurotrophic factors could prevent
neurodegenerative disease [45,46]. In particular, glial cell line-derived neurotrophic factor (GDNF)
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is associated with astrocyte activation in PD [47,48]. These findings suggest that astroglia activation
might be beneficial for preventing PD pathologies through the production of neurotrophic factors,
such as GDNF and ciliaryneurotrophic factor (CNTF). Recent research also has suggested that the
expression of transient receptor potential vanilloid 1 in astrocytes is involved in neuroprotection in PD
through the endogenous production of CNTF [49].
Although MPTP causes pathophysiological alterations in mice similar to those reported in
idiopathic PD, this neurotoxin produces transient hypokinetic behaviour and inconsistent motor
deficits that disappear within a few d of its administration [50–55]. One of the important causes of
motor dysfunction induced by MPTP is decreased levels of DA in the SN and STR, which is mainly
due to a lack of DA synthesis and storage in dopaminergic nerve endings [56]. The connection
between the SNpc and the STR is critical for producing controlled and coordinated movement. A
decrease in the levels of dopamine in this circuit results in abnormal nerve-firing patterns within
the brain that cause uncontrolled and abnormal movements. Von Bohlen (2005), reported that
the decrease in dopamine synthesis and storage in the dopaminergic nerve endings causes motor
dysfunction in PD, while MPTP-induced TH reduction in the SNpc and STR is correlated with motor
dysfunction [57,58]. To reveal behavioural correlates to MPTP-induced lesions, we used the gait, beam
and pole performance tests [59]. Our results showed that BCP improved the abnormal behaviours
in MPTP-treated mice, as manifested by the observation of a reduced total time required to climb
down the pole, prolonged latent periods in the rotarod test, and increased vertical movements. The
involvement of the CB2 receptor in the regulation of emotional behaviour suggests that this receptor
could be an important therapeutic target for the treatment of anxiety and depressive disorders. In
this sense, our results from the pole test showed that animals can generate pessimistic or dangerous
thoughts. This was determined because mice treated with BCP showed considerably decreased of
the fear caused by the pole height; the animals were very confident at the time of the test, which
resulted in decreased time required to perform the test [60]. It is known that the modulation of CB2
receptor activation leads to increased levels of endocannabinoids, such as 2-AG and AEA, which
can induce optimistic behaviour in mice. These effects of BCP were observed at a 10 mg/kg dose
administered both orally and intraperitoneally. Based on the present results, we suggest that BCP
may serve as a therapeutic agent for the alleviation of motor dysfunction by preventing dopaminergic
neuronal damage.
However, one of the limitations of this study was that the dopamine levels were not assessed
in the striatum and substantia nigra. In the animal studies, the endocannabinoid system has been
reported to activate the dopaminergic system and to increase the availability of DA in the striatum.
It is known that the DA neurons are key neurotransmitters that play a role in regulating growth,
maintenance, and synaptic plasticity.
4. Materials and Methods
4.1. Animals
All experiments were carried out using male C57BL/6J mice (25–30 g of body weight) that were
maintained under a 12:00 h light-dark cycle with food and water available ad libitum. The animals
were obtained from Harlan Laboratories (Mexico City). All animal handling and experimentation
strictly followed the Guidelines for Care and Use of Laboratory Animals published by the National
Institutes of Health and the Guidelines of the Mexican Law of Animal Protection. Animal care and
experimental procedures were in accordance with the Mexican Official Norms NOM-062-ZOO-1999
and NOM-033-ZOO-1995. All experimental procedures were approved by the research and ethics
committees of the University of Guadalajara in Mexico. We minimized the number of mice used and
their suffering or pain as much as possible.
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4.2. Drug Administration Schemes
Animals were randomly divided into four groups (n = 6/group). The first group of mice
was saline-treated and served as a control group. The second group of mice was treated with
MPTP following the subchronic scheme, which consisted of MPTP hydrochloride (30 mg/kg, i.p.;
Sigma-Aldrich, St. Louis, MO, USA) being administered daily for five consecutive days. The MPTP
administration conditions and dosage were selected based on previous studies [61] in which dopamine
depletion, apoptosis, inflammatory response, and oxidative damage were demonstrated in mice
subjected to MPTP under the same experimental conditions. The third group of mice was treated with
BCP (10 mg/kg, i.p.) for five d. The fourth group of mice was pretreated with BCP for five d, and one
day after the last administration of BCP, the animals were treated with MPTP (30 mg/kg, i.p.) for 5
consecutive days. The fifth group of mice received an administration of the CB2R antagonist AM630
(3 mg/kg, i.p., SML0327 Sigma-Aldrich) 30 min prior to an injection of another CB2R agonist, BCP.
The control mice were injected with either a CB2 agonist and an antagonist alone or a vehicle.
The animals were sacrificed 3 days after treatment was completed. To evaluate the effects of BCP
administered orally, a group of animals was administered BCP (10 mg/kg) through an oral gavage for
5 consecutive days, and one day after the last administration of BCP, the animals were treated with
MPTP (30 mg/kg, i.p.) for 5 consecutive days.
4.3. Behavioural Studies
Behavioural tests were conducted three days after the last administration of each treatment.
4.3.1. Pole Test
Bradykinesia is measured by determining the amount of time it takes an animal to turn around
and fully descend a pole according to a method described by Matsuura et al. (1997). Mice were first
acclimated to the pole (1 cm diameter, 50 cm height) in 10 trials, with each trial being separated by
120 s. In the first trial, the animals were limited to 300 s, and subsequent trials were limited to a 120 s
maximum time limit. The three best scores were averaged for each mouse [62,63].
4.3.2. Gait Test
The gait test was performed according to the method established by Fernagut et al. The apparatus
was 7 cm wide, 12 cm high and 60 cm long, finished in a dark box, and placed on an interchangeable
part [64]. The forepaw of the subject mouse was wet with non-toxic blue ink, and the mouse was
placed at the opposite end of the runway, which was covered with a strip of paper (7 cm wide and
60 cm long). The stride length of the forelimb was measured manually as the distance between two
forepaw prints. The three longest strides were measured. The first, second, and last paw prints were
excluded because the velocity changed during the run.
4.3.3. Beam Test
This test uses a device that the mice escalate consisting of a 1-metre long acrylic beam placed at
a 15-degree angle. The test mice were placed at the upper end of the beam, which was the box-home
stimulus. Initially, the mice were trained to climb a beam that was 12-mm wide for two d prior to
beginning the management schemes; the test was initiated by changing the width of the beam to 6-mm
wide. Mice were placed at the bottom of the beam and allowed to walk to reach the upper end while
recording the time it took to arrive, with a maximum limit of 120 s. After 120 s, if the mouse had not
reached its box-home manually, it was removed and placed in its box and received a rating of 120 s.
The results are expressed as the average total time (s) it took for the mice from each experimental
treatment group to run the test.
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4.4. Measurement of the IL-1β, TNF-α and IL-6 Cytokines
Analyte levels in cerebral homogenateswere measured using a commercially available Luminex
MagPix cytokine (Bio-Rad, Hercules, CA, USA) assay specific for mice according to the manufacturer’s
instructions. The MagPix assay uses a red LED instead of a laser to excite the dyes in the beads (6.5-µm
magnetic beads) for the identification of specific analytes and a green LED to excite the reporter ligand.
Acquisition of the fluorescent signal was achieved by a CCD imager. The concentration of the analytes
was determined using Bio-Plex®200 System and Bio-Plex™ Human Cytokine Standard 27-Plex, Group
I (Bio-Rad). The assays were run in triplicateof three individual experimentsand the concentrations are
expressed in pg/mL based on a standard curve.
4.5. Immunohistochemistry of Tyrosine Hydroxylase, GFAP and Iba
Three days after the last treatment was administered, the mice (n = 5 per group) were anaesthetized
(100 mg/kg ketamine and 15 mg/kg xylazine, i.p.) and an intracardiac perfusion was performed with
0.1 M PBS solution followed by 4% paraformaldehyde. After the perfusion, the brains were removed,
kept in fixative solution for 24 h, and subsequently washed 3 times with 0.1 M PBS. Coronal 35-µm
sections were sliced on a vibratome (Leica VT1000E; Leica Microsystems, Wetzlar, Germany) to obtain
the substantia nigra pars compacta (SNpc) and striatum (STR) regions. For morphological analysis of
the STR and SNpc, coronal slices were cut at the bregma and −3.3 mm from the bregma, respectively,
according to the protocol provided by Paxinos and Franklin [65]. Six tissues were collected from
each individual brain, with 175 µm between each slice. According to the coordinates mentioned
above, slices were selected at the same level in all animals to obtain a uniform analysis using the basic
principle of fractionation from the caudal face area. Analysis of the results was performed to obtain
the average number of marker-positive cells per field (445-µm) at 40×magnification cells.
4.6. Tyrosine Hydroxylase Assessment
Samples were rinsed in 0.1 M PBS and then incubated in pre-warmed sodium citrate buffer
(pH = 6) for 10 min. Next, the samples were washed three times with 0.1 M PBS and then incubated
with 1% hydrogen peroxide to block endogenous peroxidase staining. The slices were then washed
first with 0.3% Triton X-100 in 0.1 PBS, followed by an additional two washes with 0.1% Triton
X-100 in 0.1 PBS. The samples were then incubated with 10% goat serum and 0.1% Triton X-100 in
0.1 PBS for 45 min, followed by incubation for 72 h at 4 ◦C in the same buffer solution containing
a tyrosine hydroxylase antibody (Ab152 Merck Millipore, Billerica, MA, USA). The samples were
then washed (4 × 5 min) in 0.1 M PBS and incubated for 2 h at room temperature in the dark with
an anti-rabbit IgG (BA1000, Vector Labs, Peterborough, UK) antibody at a dilution 1:500. An Elite
ABC kit (Vector, PK6000) system was applied in the dark at a dilution of 1:200. The samples were
detected with 3′3 diaminobenzidine (DAB kit, Vector Labs, Peterborough, UK). To determine the
TH-immunohistochemistry in the striatum, the sections that were−3.3 mm relative to the bregma were
selected to quantify the optical densities of the TH-immunoreactive fibres according to a previously
described method [56]. TH-immunoreactive fibre density was measured in 100 × 100 µm square
images of the striatum using an image analyser (Multiscan, Fullerton, CA, USA).
4.7. GFAP and Iba Assessment
Other tissue sections were processed to identify astrocyte and microglial cells. To identify
astrocytes immunocytochemically, washes and incubations were performed on free-floating tissue
sections while being moderately shaken. Briefly, tissue sections were incubated in 1% hydrogen
peroxide to block endogenous peroxidase staining. Next, the slices were washed (4 × 5 min) with
0.1 Triton X-100 in 0.1 PBS and then incubated for 45 min with 0.1 Triton X-100 in 0.1 PBS and 10%
goat serum. The slices were incubated in this same buffer overnight at 4 ◦C with an anti-glial fibrillary
acidic protein (GFAP) polyclonal antibody (DAKO, Glostrup, Denmark) at a dilution of 1:400 and
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an anti-rabbit IgG secondary antibody (BA1000, Vector Labs). Then, complex incubation using the Elite
ABC kit (Vector, PK6000) was performed in the dark for 2 h at a dilution 1:200. After being washed
with 0.1 M PBS, the tissue sections were detected with 3′3-diaminobenzidine.
Histochemical staining of microglia was performed as follows: To inhibit peroxidase activity,
sections were incubated for 20 min with 1% H2O2. Tissues were rinsed in 0.1 M PBS (4 × 5 min) and
incubated for 45 min in 0.1 M PBS and 10% goat serum. They were then incubated overnight at 4◦C
with lectin from Bandeiraea BS-1.
5. Statistical Analysis
Statistical analysis was performed using GraphPad Prism5 software (GraphPad Software, Inc.,
La Jolla, CA, USA). Data are expressed as the means ± SD. The multiple comparison one-way analysis
of variance and Tukey’s HSD post hoc tests were used for statistical analysis. p-values ≤ 0.05 were
considered statistically significant.
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CB1R type 1 cannabinoid receptor
CB2R type 2 cannabinoid receptor
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
GFAP glial fibrillary acidic protein
TH tyrosine hydroxylase
CNS central nervous system
NO nitric oxide
ROS oxygen species
GDNF line-derived neurotrophic factor (GDNF)
CNTF ciliary neurotrophic factor
SNpc substantia nigra pars compacta
STR striatum
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